Symbiotech Pharmalab IPO: 35% Premium, Strong Investor Demand
Key Highlights
Symbiotech Pharmalab IPO garners significant investor interest, with a Grey Market Premium of ₹350, suggesting a 35.43% listing premium. IPO details and subscription status.
Symbiotech Pharmalab Ltd’s indicates significant investor interest, with an estimated listing price of ₹1,338, representing a 35.43% premium over its issue price.
The public offering, which launched on August 24, 2026, has already seen substantial subscription across key investor categories.
Key IPO Numbers
- : ₹1,757 crore
- : ₹938 to ₹988 per share
- : 15 shares
- Overall (as of August 25, 2026): 1.71 times
The (GMP) for Symbiotech Pharmalab Ltd IPO stands at ₹350 as of August 25, 2026.
This GMP suggests a listing at ₹1,338, though such premiums are speculative and do not guarantee actual listing performance.
Investor Subscription Breakdown
- Small Non-Institutional Investors (S-): 3.65 times
- Investors: 2.00 times
- (QIB): 0.57 times
QIB demand was lower initially, but institutional bidding often increases closer to the closing date.
The IPO concludes on Thursday, August 27, 2026, with allotment expected on August 28, 2026, and listing on September 1, 2026.
The GMP saw an upward trend, peaking at ₹410 on August 22 before moderating to its current level.
Investors are advised to monitor final subscription data and broader market conditions as the IPO progresses.